Report Summarizes Kinase Inhibitors Study Findings from Saga University Hospital (Simulation of Perioperative Ibrutinib Withdrawal Using a Population Pharmacokinetic Model and Sparse Clinical Concentration Data): Drugs and Therapies – Kinase Inhibitors

2025 DEC 15 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- A new study on Drugs and Therapies - Kinase Inhibitors is now available. According to news reporting originating in Saga, Japan, by NewsRx journalists, research stated, “PurposeTreatment with the Bruton tyrosine kinase inhibitor ibrutinib carries a significant risk of bleeding; therefore, the risk-benefit assessment regarding withholding ibrutinib pre- and post-surgery should be considered based on the type of surgery being planned. However, there is no optimal rationale regarding ibrutinib withdrawal during the perioperative period.”

Financial supporters for this research include Taiju Life Insurance Company, Fukuda Foundation for Medical Technology, Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science.

The news reporters obtained a quote from the research from Saga University Hospital, “This exploratory study aimed to generate hypotheses regarding perioperative management of ibrutinib therapy by simulating individual pharmacokinetic profiles using a previously reported population pharmacokinetic (PopPK) model.MethodsPlasma levels of ibrutinib were measured in patients receiving ibrutinib and at high risk of bleeding at Saga University Hospital. Using Phoenix NLME, Bayesian estimation, based on a previously reported PopPK model incorporating actual plasma concentrations measured in individual patients, was employed to simulate perioperative withdrawal scenarios.ResultsFive patients were enrolled. After a withdrawal period of 3-7 days there were no bleeding events in patients that underwent surgery with a low bleeding risk; however, bleeding events occurred in one patient that underwent gastrectomy with moderate or higher bleeding risk. The AUC0-24 for ibrutinib in a patient also receiving isavuconazole, a moderate CYP3A4 inhibitor, was 1,979 ng*h/mL, a value 2.4-4.8 times higher than that in the patients not receiving isavuconazole.ConclusionPerioperative withdrawal of ibrutinib was explored using a previously reported PopPK model in combination with sparse plasma concentration data obtained from patients in real-world clinical settings, including those undergoing surgery.”

According to the news reporters, the research concluded: “This exploratory study suggests that reliance on plasma concentration data alone might be inadequate for determining the optimal perioperative withdrawal period of ibrutinib.”

This research has been peer-reviewed.

For more information on this research see: Simulation of Perioperative Ibrutinib Withdrawal Using a Population Pharmacokinetic Model and Sparse Clinical Concentration Data. Cancer Chemotherapy and Pharmacology, 2025;95(1). Cancer Chemotherapy and Pharmacology can be contacted at: Springer, One New York Plaza, Suite 4600, New York, Ny, United States. (Springer - www.springer.com; Cancer Chemotherapy and Pharmacology - http://www.springerlink.com/content/0344-5704/)

Our news correspondents report that additional information may be obtained by contacting Sakiko Kimura, Saga University Hospital, Dept. of Pharmacy, 5-1-1 Nabeshima, Saga 8498501, Japan. Additional authors for this research include Nao Kikkawa, Shunsuke Matsuo, Chisato Shimanoe, Ken-ichi Sako, Yuta Nakamaru, Kana Kusaba, Mai Fujita, Keisuke Kidoguchi, Sho Okamoto, Shinya Kimura and Yukie Yoda.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s00280-025-04816-2. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)